Early Stage
Differences in IMRT Radiation Doses May Complicate Study Results in Lymphomas
(04/07/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in lymphomas difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.
Hodgkin’s Lymphoma Survivors May Be at Risk for Secondary Cancer
(02/29/2008)
Hodgkin’s lymphoma survivors may be at risk for secondary cancer. These findings were recently reported in the British Journal of Cancer.
Better Prognosis for Patients with Lymphocyte-predominant Hodgkin’s Lymphoma
(02/05/2008)
A recent study compared lymphocyte-predominant Hodgkin’s lymphoma (LPHL) and classical Hodgkin’s lymphoma (cHL) in order to define differences in patient characteristics and possible treatment options for both types of disease. These results were published in the Journal of Clinical Oncology.
Annual Mammography Alone Not Sufficient for Young Hodgkin’s Survivors
(01/09/2008)
According to the results of a study published in the Annals of Oncology, annual screening mammography may miss some cases of early invasive breast cancer among young Hodgkin’s lymphoma survivors who were treated with supradiaphragmatic (above the diaphragm) radiation therapy.
Chemotherapy plus Radiation Recommended as Standard of Care in Early Hodgkin’s
(11/09/2007)
According to an article recently published in the New England Journal of Medicine, chemotherapy plus involved-field radiation should become the standard of care for early-stage Hodgkin’s disease.
More...
Advanced Stage
Hodgkin’s Lymphoma Survivors May Be at Risk for Secondary Cancer
(02/29/2008)
Hodgkin’s lymphoma survivors may be at risk for secondary cancer. These findings were recently reported in the British Journal of Cancer.
Better Prognosis for Patients with Lymphocyte-predominant Hodgkin’s Lymphoma
(02/05/2008)
A recent study compared lymphocyte-predominant Hodgkin’s lymphoma (LPHL) and classical Hodgkin’s lymphoma (cHL) in order to define differences in patient characteristics and possible treatment options for both types of disease. These results were published in the Journal of Clinical Oncology.
Patients with Hodgkin’s at Risk for Heart Attack Later in Life
(02/14/2007)
According to results from the Journal of the National Cancer Institute, patients treated for Hodgkin’s lymphoma are at an increased risk for death from a heart attack for 25 years.
Increase in Hodgkin’s Lymphoma in HAART Era
(01/03/2007)
Among people living with AIDS, the frequency of Hodgkin’s lymphoma has increased since the introduction of highly active antiretroviral therapy (HAART). These results were published in the journal Blood.
Neulasta® Safe and Effective for Hodgkin’s Patients Treated with ABVD Chemotherapy
(11/07/2006)
Among Hodgkin’s lymphoma patients treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy every two weeks, use of Neulasta® (pegfilgrastim) was safe and allowed most patients to receive their chemotherapy on schedule. These results were published in the European Journal of Cancer.
More...
Progressive Relapsed
Patients with Hodgkin’s at Risk for Heart Attack Later in Life
(02/14/2007)
According to results from the Journal of the National Cancer Institute, patients treated for Hodgkin’s lymphoma are at an increased risk for death from a heart attack for 25 years.
Increase in Hodgkin’s Lymphoma in HAART Era
(01/03/2007)
Among people living with AIDS, the frequency of Hodgkin’s lymphoma has increased since the introduction of highly active antiretroviral therapy (HAART). These results were published in the journal Blood.
Addition of Interferon Following an Autologous Stem Cell Transplant Provides Impressive Outcomes for Children with Recurrent Hodgkin's
(08/29/2006)
According to an article recently published in Bone Marrow Transplantation, the addition of the biologic agent interferon following an autologous stem cell transplant provides impressive outcomes for pediatric patients with Hodgkin's lymphoma that has stopped responding to prior therapies.
Certain Variables Predict Risk of Secondary Leukemia After Stem Cell Transplant
(07/31/2006)
According to an article recently published in the Journal of Clinical Oncology, patients diagnosed with lymphoma who were previously treated with radiation therapy, those treated with four or more chemotherapy regimens, and those who take five days to collect enough stem cells for a transplant are at a higher risk of developing myelodysplastic syndromes or acute myeloid leukemia associated with a stem cell transplant.
Hodgkin’s Survivors: Increased Fatigue, Cardiac, and Thyroid Complications
(12/02/2005)
According to a recent article published in the Annals of Oncology, survivors of Hodgkin’s lymphoma have a significantly increased rate of cardiac and thyroid complications than their siblings. In addition, survivors tend to have more fatigue than their siblings; however, this may in part be associated with cardiac issues.
More...